VeriSilicon Unveils Next-Generation High-Performance Vitality Architecture GPU IP Series
Empowering efficient cloud gaming with DirectX 12 support and advanced computingcapabilities
VeriSilicon (688521.SH) today announced the launch of its latest Vitality architecture Graphics Processing Unit (GPU) IP series, designed to deliver high-performance computing across a wide range of applications, including cloud gaming, AI PC, and both discrete and integrated graphics cards.
VeriSilicon’s new generation Vitality GPU architecture delivers exceptional advancements in computational performance with scalability. It incorporates advanced features such as a configurable Tensor Core AI accelerator and a 32MB to 64MB Level 3 (L3) cache, offering both powerful processing power and superior energy efficiency. Additionally, the Vitality architecture supports up to 128 channels of cloud gaming per core, addressing the needs of high concurrency and high image quality cloud-based entertainment, while enabling large-scale desktop gaming and applications on Windows systems. With robust support for Microsoft DirectX 12 APIs and AI acceleration libraries, this architecture is ideally suited for a wide range of performance-intensive applications and complex computing workloads.
With over 20 years of development, VeriSilicon’s GPU IP has a proven track record in diverse segments, from low-power IoT Microcontroller Units (MCUs) to high-performance processors for automotive and computing applications. To date, over 2 billion chips featuring VeriSilicon’s GPU IP have been shipped globally.
“Parallel computing demand has been steadily increasing over the last decade, with a dramatic surge driven by the rise of AI computing. GPUs have become essential processors in this new era, expanding their role beyond traditional applications like gaming,” said Weijin Dai, Chief Strategy Officer, Executive Vice President and General Manager of IP Division at VeriSilicon. “The Vitality architecture GPU represents the next generation of high-performance and energy-efficient GPU. With over 20 years of GPU development experience across diverse market segments, the Vitality architecture is built to support the most advanced GPU APIs. Its scalability enables widespread deployment in fields such as automotive systems and mobile computing devices. We are thrilled to collaborate with leading customers to integrate this groundbreaking technology into their products, addressing the growing demand for GPUs and advanced computing solutions.”
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241217414024/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global udvider sit servicetilbud i Japan med tilføjelse af Kohwa Sohgoh18.12.2024 17:54:00 CET | Pressemeddelelse
Andersen Global udvider sine muligheder i Japan gennem en samarbejdsaftale med advokatvirksomheden Kohwa Sohgoh. Med denne virksomhed får vi et supplement til den skatteekspertise, vi har i landet. Med mere end 35 års erfaring tilbyder Kohwa Sohgoh, med kontor i Tokyo, et omfattende udvalg af juridiske tjenester til kunder inden for forskellige sektorer. Virksomhedens team af fagfolk er specialister i selskabsret, forvaltningsret, strafferet, familieret og civilret samt compliance, omstrukturering, ansættelse, intellektuel ejendomsret, grænseoverskridende transaktioner, finansiering og fast ejendom. Kohwa Sohgoh arbejder tæt sammen med både private og offentlige virksomheder og leverer skræddersyede løsninger til komplekse forretningsmæssige og juridiske udfordringer. "Vi har forpligtet os på at yde kontinuerlig og omfattende support til vores kunder og fremme langsigtede relationer, der bygger på tillid og ekspertise," siger partner Shunsuke Nohara. "Samarbejdet med Andersen Global gi
Brightcove Drives Global Customer Growth and Value Through Strategic Partnerships with Leading MarTech Solutions18.12.2024 16:59:00 CET | Press release
Brightcove is helping customers build and deploy comprehensive martech stacks for advanced video management through seamless partner integrations Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, is sharing significant enhancements to its platform through strategic partnerships to enhance the video content creation, distribution and monetization process. As part of the goal to help customers build more cohesive, easy-to-deploy martech stacks, Brightcove has integrated capabilities from companies like Acquia that deliver additional benefits to customers. “As we build strategic partnerships with key providers, we continually look at ways to help our customers reach their business goals. With the right partners, we enable marketers to fully leverage their content and get the most value out of it,” said David Beck, Chief Operating Officer at Brightcove. “Integrating our partners’ strengths – like Acquia’s DAM capabilities – seamlessly into Brightcove’s platf
GC Aesthetics® Announces Decade-Long Clinical Evaluation of PERLE™ Breast Implants18.12.2024 16:56:00 CET | Press release
GC Aesthetics® (GCA), a privately-held medical technology company providing aesthetic and reconstruction solutions for global healthcare markets, is proud to announce the initiation of a significant multi-center and prospective clinical study in Europe to evaluate, and confirm, the safety, effectiveness, and patient satisfaction associated with the innovative PERLE™ smooth opaque round breast implant. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241218630395/en/ GC Aesthetics' PERLE™ Breast Implant features a proprietary surface technology (BioQ™) and GCA’s industry-leading gel technology (Emunomic™ Breast Tissue Dynamic Gel). (Photo: Business Wire) This extensive study brings together leading surgeons from the NHS and private clinics in the UK, as well as from private practices across Europe, ensuring a robust and diverse dataset that addresses both cosmetic and reconstructive indications. “By generating high-quality clin
Novotech Publishes Report on the Global COVID-19 Clinical Trial Landscape, Highlighting Key Trends, Therapeutic Advancements, and Challenges in Drug Development18.12.2024 14:05:00 CET | Press release
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics, has released an in-depth report "COVID-19: Global Clinical Trial Landscape 2024." This report delivers a robust analysis of ongoing and completed COVID-19 clinical trials, therapeutic strategies, and funding trends, offering essential insights for researchers and biotech leaders in the evolving COVID-19 research landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241218899045/en/ The COVID-19 pandemic has led to significant advancements in clinical research and therapeutic innovation. Novotech’s report offers an authoritative analysis of global trial distribution, patient recruitment trends, and emerging therapeutic strategies, drawing on over 5,000 clinical trials conducted since 2019 across Asia-Pacific, North America, Europe, and beyond
Novotech Releases Report on Global Parkinson’s Disease Clinical Trial Landscape18.12.2024 14:05:00 CET | Press release
Novotech, the global full-service clinical Contract Research Organization (CRO), announces the release of its report, Parkinson’s Disease: Global Clinical Trial Landscape 2024. This report provides critical insights into the trends, opportunities, and challenges in Parkinson's disease (PD) research, serving as a valuable resource for companies developing treatments for this complex neurodegenerative disorder. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241218606779/en/ Report Highlights Parkinson’s disease is one of the fastest-growing neurological conditions, with prevalence expected to double by 2030. This report analyzes global clinical trial data, offering biotech and pharmaceutical companies key information to guide clinical development strategies. Key findings include: Global Trial Distribution: Review of over 750 PD trials initiated since 2019, with Asia-Pacific leading at 44% of trials. Major regions include China
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom